CARBOTERO contains carboplatin, an antineoplastic platinum compound. After administration, the drug interacts with cellular DNA and produces DNA damage that interferes with normal DNA replication and repair. This inhibits the division and growth of rapidly proliferating tumor cells.
The medication may be used:
Carboplatin has been extensively evaluated in clinical trials and comparative studies with cisplatin. In advanced ovarian cancer, platinum-based chemotherapy combinations have demonstrated clinical benefit, while carboplatin has become widely used because of its distinctive toxicity profile. Meta-analyses of randomized trials have found broadly comparable efficacy between carboplatin and cisplatin in several clinical settings, although their adverse-effect profiles differ.
Current clinical recommendations continue to include carboplatin-based regimens for ovarian cancer. For example, the current ASCO guideline for recurrent epithelial ovarian cancer includes carboplatin combinations with agents such as paclitaxel, gemcitabine, and pegylated liposomal doxorubicin for platinum-sensitive recurrence.
Studies of carboplatin combined with paclitaxel also support the important role of this regimen in systemic treatment of epithelial ovarian cancer. Systematic reviews and meta-analyses provide substantial clinical evidence while emphasizing the need for careful monitoring of hematologic toxicity.
Carboplatin is used to treat certain malignant tumors, particularly ovarian cancer and selected forms of lung cancer. Depending on the diagnosis, it may be administered as part of combination chemotherapy.
The drug belongs to the platinum class of antineoplastic agents. Its anticancer activity is associated with DNA damage in tumor cells, disrupting DNA replication and cell division. Specific indications, drug combinations, and treatment schedules are determined by the oncologist based on tumor type and stage, the patient's overall condition, kidney function, and other clinical factors.
CARBOTERO is administered intravenously by a healthcare professional in a specialized medical setting. The carboplatin dose is individualized, commonly taking renal function and the target drug exposure into account, and may vary according to the oncology protocol being used. The solution may be diluted before administration according to the manufacturer's instructions and the prescribed treatment regimen. Self-administration is strictly inappropriate.
Side Effects
The most important dose-limiting toxicity of carboplatin is bone marrow suppression. Regular blood-count monitoring is therefore required during treatment.
